Evonik stock slips to EUR 20.90, down 1.04% premarket
Published on 11/10/2026 at 07:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSTakeover talks keep focus on strategy
- Evonik continues to reject BASF's increased EUR 24 takeover offer after weekend discussions.
- No further meetings between the two companies are currently scheduled.
- Management is maintaining its focus on Evonik's independent strategy and planned restructuring.
Evonik stock traded at EUR 20.90 on Lang & Schwarz at 08:44 CET on Tuesday, November 10, 2026, 1.04% below the Xetra close of Monday, November 9, 2026 at EUR 21.12.
Takeover debate remains the central catalyst
Chief executives and chief financial officers from Evonik and BASF held preliminary talks over the weekend, according to Reuters. Evonik continues to oppose BASF's increased offer of EUR 24 per share, which values the specialty chemicals group at about EUR 11.18 billion. The discussions did not lead to formal acquisition negotiations, and no further meetings are currently scheduled.
The market focus therefore remains split between Evonik's independent strategy and the potential value of BASF's proposal. Evonik had already rejected the higher offer and said it was not sufficient to begin formal deal talks. The company is continuing to pursue its own restructuring and development plan while keeping the dialogue with BASF confidential and informative.
Recent operating momentum provides the strategic backdrop. Evonik reported third-quarter adjusted EBITDA of EUR 629 million, up 40% year over year, and management expects full-year adjusted EBITDA in the upper half of its EUR 2.0 billion to EUR 2.2 billion range, according to Industrylinqs.
In the wider German market, investors are also monitoring the DAX.
Further company developments remain relevant for more news and analyses on Evonik stock.
